Etadexe-MEZ (Drops) Instructions for Use
Marketing Authorization Holder
Moscow Endocrine Plant FSUE (Russia)
ATC Code
S01XA (Other preparations for the treatment of eye diseases)
Dosage Form
| Etadexe-MEZ | Ophthalmic drops 0.5%: tube-dropper 1.3 ml, bottle 5 ml with dropper cap, bottles 5 ml. |
Dosage Form, Packaging, and Composition
| Ophthalmic drops 0.5% | 1 ml |
| Hydroxyethylaminoadenine hydrobromide | 5 mg |
Excipients: purified water, dextran 60, sodium methylparaben.
1.3 ml – tube-droppers (2) – cardboard packs.
5 ml – bottles (1) with a dropper cap – cardboard packs.
5 ml – bottles (1) – cardboard packs.
Clinical-Pharmacological Group
A drug that stimulates regeneration processes for topical use in ophthalmology
Pharmacotherapeutic Group
Tissue regeneration stimulant
Pharmacological Action
Etaden-8-(2-hydroxyethyl)-aminoadenine hydrobromide monohydrate.
A purine derivative, a stimulator of reparative cell regeneration. The mechanism of action is associated with the activation of nucleic acid synthesis.
It accelerates reparative processes, primarily in rapidly renewing tissues (epithelial and hematopoietic).
It reduces edema, pain, and increases visual acuity. It promotes the regeneration of corneal defects, the formation of a scar, and the restoration of a smooth spherical surface of the cornea.
Indications
Stimulation of corneal epithelium regeneration in various eye lesions accompanied by a violation of its epithelial integrity: epitheliopathy after infectious and inflammatory diseases; dry eye syndrome (in combination with artificial tear preparations); bullous keratopathy; initial epithelial-endothelial dystrophy; epithelial defects after ophthalmic surgeries (cataract removal, glaucoma surgery); postoperative descemetitis; recurrent erosions; ulcers of bacterial, fungal, and herpetic etiology (as part of combination therapy); burns; keratitis with ulceration and damage to the superficial layers of the cornea.
ICD codes
| ICD-10 code | Indication |
| H04.1 | Other disorders of lacrimal gland (dry eye syndrome) |
| H16 | Keratitis |
| H16.0 | Corneal ulcer |
| H16.8 | Other forms of keratitis |
| H18.1 | Bullous keratopathy |
| H18.4 | Corneal degeneration |
| H18.5 | Hereditary corneal dystrophies |
| H18.8 | Other specified disorders of cornea |
| T26 | Thermal and chemical burns confined to the eye and its adnexa |
| ICD-11 code | Indication |
| 9A1Z | Diseases of the lacrimal system, unspecified |
| 9A70.Z | Hereditary corneal dystrophies, unspecified |
| 9A71 | Infectious keratitis |
| 9A76 | Corneal ulcer |
| 9A78.20 | Bullous keratopathy |
| 9A78.4 | Corneal degeneration |
| 9A78.Z | Other diseases of cornea, unspecified |
| 9A7Z | Diseases of the cornea, unspecified |
| NE00 | Burn of eye and adnexa |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Topically, as instillations into the conjunctival sac – 2-3 drops 3 times/day.
Depending on the etiology of the process and the severity of the organ damage, the local prescription of other specific and symptomatic medications is possible in parallel.
The duration of treatment depends on the course of the disease and should not exceed 10 days.
The absence of a therapeutic effect when using the drug for 10 days indicates the need to use other methods of treatment.
Adverse Reactions
Allergic reactions.
Contraindications
Hypersensitivity.
Special Precautions
Freezing of the solution is not allowed.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Rx Only
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer